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The faecal immunochemical test (FIT) is used in colorectal cancer (CRC) screening and for
the detection of advanced colorectal neoplasia (AN) in symptomatic patients, but its accu-
racy could be improved. Our objective was to assess the impact of proton pump inhibitors
(PPI) on the accuracy of the FIT in the detection of AN, namely advanced colorectal ade-
noma and CRC.
Methods and findings
We performed a prospective study of 1002 individuals referred for a diagnostic colonoscopy
at Bellvitge University Hospital from September 2011 through to October 2012. An exhaus-
tive interview was performed by a gastroenterologist, prescription drug dispensing database
was reviewed and the patient was given a FIT prior to colonoscopy. The positivity threshold
of FIT used was 20 μg Hb/g feces and the main outcome was AN. AN was detected in
13.2% (133) of patients. The accuracy of FIT for detecting AN in the PPI users and non-PPI
users were: sensitivity 43.0% vs 65.6%, P = 0.009; specificity 86.9% vs 92.3%, P = 0.010;
and, predictive positive value 34.4% vs 55.5%, P = 0.007, respectively. In multivariate analy-
sis, adjusting for potential confounders, PPIs were associated with false positives in AN
detection by FIT (OR 1.63 CI 95% 1.02–2.59, P < 0.037). The ROC curve for the FIT in the
detection of AN in the PPI users and non-PPI users was 0.68 (CI 95% 0.61–0.76) and 0.85
(CI 95% 0.79–0.90).
Conclusions
PPI therapy reduces the accuracy of FIT for detecting AN in symptomatic patients.
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Introduction
Periodic faecal occult blood testing, and subsequent colonoscopy if the result is positive, is a
widely accepted strategy for colorectal cancer (CRC) screening in average risk population [1–
3]. Faecal biochemical tests based on the oxidation of guaiac have been used for this purpose
for years resulting in a reduction in CRC-related mortality [4]. Recently, guaiac-based faecal
tests are being replaced by faecal immunochemical tests (FIT) that are able to detect smaller
amounts of hemoglobin in faeces (60 μg Hb/g faeces vs 10 μg Hb/g faeces) by using antibodies
to human globin. FITs are more sensitive for the detection of CRC and advanced neoplasia
(AN) in comparison to the guaiac-based faecal tests [1]. Furthermore, recent studies have dem-
onstrated that quantitative FIT is also an objective and accurate method for detecting advanced
neoplasia (AN), including advanced adenoma and colorectal cancer, in symptomatic patients.
In fact, FIT has shown a better discriminatory ability than lower abdominal symptoms [5–9].
Nevertheless, its accuracy in the detection of advanced adenoma (AA) is far from perfect. The
sensitivity of the FIT for CRC is relatively high, at over 85%, but its sensitivity for advanced
adenoma (AA) is under 40% [9–11]. AA is associated with a relatively high risk of progression
to cancer and is considered the optimal target lesion to prevent colorectal cancer [12–14]. For
this reason, improving the diagnostic accuracy of the FIT in the identification of AA and the
factors that are likely to influence the accuracy of the FIT is of great importance for the study
of symptomatic patients and the CRC screening programme.
Proton pump inhibitors (PPI) are widely prescribed drugs due to their extensive indica-
tions, including dyspepsia, gastroesophageal reflux and the prevention of gastrointestinal
bleeding in patients on antiplatelet therapy or non steroidal anti-inflammatory drugs
(NSAID). PPI are associated with a large number of effects on the gastrointestinal tract [14,
15] that potentially could affect FIT accuracy. Changes in the gastrointestinal microbiome
[16], an increase in the incidence of NSAID-induced small bowel injuries [17] and inhibition
of pancreatic secretion [18–20] have been described in patients on PPI treatment. Recently, a
study performed by Ibañez et al. to evaluate the influence of prescription drugs on the accuracy
of FIT in colorectal cancer screening found that the use of PPI was associated with false-posi-
tive results of FIT [21]. Nevertheless, this study did not include the result of the colonoscopy of
patients with a negative FIT and in consequence, the influence of PPI on the sensitivity and
specificity of the test could not be ascertained. Therefore, we hypothesized that PPI may mod-
ify the precision of the FIT. The objective of this study is to evaluate the impact of PPI treat-
ment on the accuracy of the FIT for detecting AN (AA or CRC).
Methods
Study design and patients
This is a post hoc analysis of a previous study that evaluated an urgent referral strategy based
on a quantitative FIT for symptomatic patients with suspected colorectal cancer (Rodriguez
Alonso et al, 2015) [6]. Briefly, the study included symptomatic patients of more than 18 years
of age referred for diagnostic colonoscopy to the Endoscopy Unit of the Bellvitge University
Hospital between September 2011 and October 2012, S1 File. Patients referred for adenoma
and CRC surveillance, history of previous colectomy, inflammatory bowel disease, polyposis
syndromes and hospitalized patients were excluded. Patients with incomplete colonoscopies
were only included if its cause was a stenosing neoplasm. Referrals were outpatient requests
from general practitioners and community gastroenterologists, as well as hospital requests. An
exhaustive questionnaire was administered by a gastroenterologist in a face-to-face interview.
In this consultation signs, symptoms, CRC risk factors and, use of medical drugs, including
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PPI intake and dose were recorded and a specimen collection device of FIT (OC Sensor1,
Eiken Chemical Co., Ltd., Tokyo, Japan) and the instructions on how to perform and storage
the test at home were given [6]. Samples with collection or storage errors were excluded from
the study. All tests were analyzed using the OC sensor MICRO desktop analyser (Eiken Chem-
ical1Co., Ltd., Tokyo, Japan). In our study, FIT 20 μg Hb/g feces was taken as the cut-off
value. The endoscopist and the technician were blind to the patient data and FIT results. All
colonoscopies were performed by experienced endoscopists. Conscious sedation was adminis-
tered using intravenous propofol. The colonoscopy was considered complete if caecal intuba-
tion was achieved as demonstrated by the visualization of the ileocecal valve or the appendiceal
orifice. The bowel preparation was considered adequate according the validated Boston bowel
preparation scale. Recorded data included the number, size and histology of polyps and, the
presence or absence of CRC. The study protocol was approved by University Hospital of Bell-
vitge Ethics Committee, reference number PR 283/11 S2 File, and written informed consent
was obtained from all patients.
Outcome measures
The dependent variables analyzed were the detection of AN and CRC. AN was defined as the
presence of AA (adenoma 10 mm, villous component or high-grade dysplasia) or invasive
carcinoma. The following independent variables were evaluated for their potential association
with AN or CRC: age, gender, tobacco or alcohol use including former or current exposure,
family history of CRC, history of colorectal adenoma, dyslipidemia, diabetes mellitus, body
mass index, antiplatelet therapy, anticoagulant therapy or NSAID use, iron deficiency anaemia
(IDA), abdominal symptoms or signs and, FIT result. Average alcohol consumption (in stan-
dard units of alcohol, SUA), was categorized into low-risk and high-risk consumption (> 4
SUA/ day in men and> 2 SUA/day in women) [22]. Abdominal symptoms or signs consid-
ered as high risk symptoms, according NICE Guideline criteria were recorded such as patients
with IDA (Hb11 g/dl in men or10 g/dl in postmenopausal women), a definitive palpable
right-sided abdominal mass or a rectal mass, patients over the age of 40 years with rectal bleed-
ing and diarrhoea for six week, and patients over the age of 60 years with rectal bleeding or
diarrhoea for six weeks [23].
Exposure to proton pump inhibitors
Exposure for each patient was determined from the interview and confirmed with computer-
ized prescriptions recorded. Patients were considered exposed if they intake regularly PPI—
omeprazole, lansoprazole, pantoprazole, rabeprazole, or esomeprazole—during the past 90
days or sporadic consume during the past 30 days before the interview date.
Statistical analysis
Univariate and multivariate analyses were performed to evaluate the accuracy of FIT in the
identification of AN and CRC depending on PPI use. The chi-squared test was used to assess
the association between categorical data and the detection of AN and CRC in both PPI users
and non-PPI users. We evaluated the diagnostic accuracy of positive FIT for advanced neopla-
sia and colorectal cancer according to proton pumps inhibitors treatment. The outcome mea-
sures were sensitivity, specificity, positive predictive value, negative predictive value, overall
value, positive likelihood ratio and negative likelihood ratio.
A multivariate analysis based on a forward conditional logistic regression procedure was
performed in order to identify independent predictive factors of false positives (FP) of the FIT
in the detection of AN and CRC. These factors were included in the multivariable model based
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on their univariate association with AN and CRC (P< 0.05). Factors not reaching statistical
significance were also included if they were considered to be clinically relevant or biologically
plausible with a sound scientific rationale. The results of the model are reported as adjusted
odds ratios (OR) and their 95% confidence intervals (CI). Statistical analysis was carried out
using SPSS, Version 17, Inc, Chicago, IL.
Results
Descriptive findings
During the study period, 1003 patients were enrolled in the study. One individual was
excluded due to the pharmacological history of the patient could not be confirmed in the elec-
tronic prescription registry. Finally, the data of 1002 patients were analyzed. As described in
detail elsewhere [6], 133 patients were found to have AN (13.3%), including 103 patients with
advanced adenoma (10.3%) and 30 patients with CRC (3.0%). Non-advanced adenoma was
identified in 168 patients (16.8%). Colonoscopy resulted normal in 600 patients (59.8%)
and other conditions, such as inflammatory or vascular lesions, were found in 101 patients
(10.1%). A total of 398 (39.7%) patients were chronic PPI users, 157 (15.7%) due to prevention
of gastrointestinal damage in patients on antiplatelet or NSAID therapy and 241 (24.0%) due
to different conditions such as dyspepsia or gastroesophageal reflux disease. One hundred and
twenty-seven (12.7%) patients were sporadic users due to episodic treatment of gastroesopha-
geal reflux disease. A total of 525 (52.4%) patients were considered as PPI users. Demographic
and clinical characteristics of patients and endoscopic findings according to PPI use are shown
in Table 1. There were significant differences in age, smoking status, dyslipidemia, diabetes
and the therapy with NSAIDs or antiplatelet agents between the PPI and the non-PPI users.
The prevalence of high risk symptoms according NICE Guideline criteria by PPI use are
shown in Table 2. There were significant differences between the PPI and the non-PPI users in
the prevalence of IDA (18.6 vs 5.4, P< 0.001) and in the prevalence of patients over the age of
60 years with rectal bleeding for six weeks without anal symptoms (6.1 vs 3.1, P = 0.027).
Table 1. Demographic and clinical characteristics and endoscopic findings of patients according to PPI use.
Variable PPI users Non PPI users P Value
PPI therapy, n (%) 525 (52.4) 477 (47.6)
Age (years), mean +/- SE 64.9 ± 11.3 57.3 ± 14.0 < 0.001
Male sex, n (%) 232 (44.2) 238 (49.8) 0.071
Smoking status (former or current), n (%) 228 (43.4) 235 (49.2) 0.047
High risk consumption of alcohol, n (%) 108 (20.6) 108 (22.6) 0.327
Dyslipidemia, n (%) 283 (53.9) 168 (35.2) < 0.001
Diabetes Mellitus, n (%) 137 (26.1) 60 (12.5) < 0.001
Body mass index 30kg/m2, n (%) 147 (28.0) 107 (22.4) 0.100
NSAID/antiplatelet agents users, n (%) 182 (34.6) 63 (13.2) <0.001
FIT 20 μg Hb/g, n (%) 90 (17.1) 70 (14.6) 0.379
Size of Advanced Adenoma (mm), mean +/- SE 12.1± 8.4 13.0± 7.8 0.640
Proximal location of Advanced Neoplasia, n (%) 30 (5.7) 18 (3.8) 0.203
Advanced Neoplasia, n (%) 72 (13.7) 61 (12.8) 0.666
Advanced adenoma, n (%) 57 (10.8) 46 (9.6) 0.528
Colorectal cancer, n (%) 15 (2.8) 15 (3.1) 0.790
NSAID: non steroidal anti-inflammatory drugs,
Right colon lesions
https://doi.org/10.1371/journal.pone.0203359.t001
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Diagnostic accuracy of FIT according to PPI treatment
The diagnostic accuracy of the FIT for the detection of AN in the whole population was: sensi-
tivity 53.4%; specificity 89.4%; predictive positive value (PPV) 43.6%, negative predictive value
(NPV) 92.6%, positive likelihood ratio (PLR) 5.0 and negative likelihood ratio (NLR) 0.5. The
diagnostic accuracy of the FIT in the PPI users and non- PPI user is showed in Table 3. The
PLR and NLR in PPI users were: 3.3 and 0.6, respectively. The PLR and NLR in non—PPI
users were: 8.5 and 0.4, respectively.
The diagnostic accuracy of the FIT for the detection of CRC in the whole population was:
sensitivity 93.3%; specificity 86.1%; PPV 17.2%, NPV 99.8%, PLR 6.7 and NLR 0.5. The diag-
nostic accuracy of the FIT in the PPI users and non- PPI user is showed in Table 4. The PLR
and NLR in PPI users were: 6.3 and 0.1, respectively. The PLR and NLR in non—PPI users
were: 7.4 and 0.1, respectively.
The diagnostic accuracy of the FIT for advanced adenoma is provided in the Supplementary
Table 1. The area under the ROC curves for the FIT in the detection of AN, AA and CRC was
0.76 (CI 95% 0.71–0.81), 0.68 (CI 95% 0.63–0.75) and 0.94 (CI 95% 0.91–0.96), respectively.
The ROC curve for the FIT in the detection of AN in the PPI users and non-PPI users was
0.68 (CI 95% 0.61–0.76) and 0.85 (CI 95% 0.79–0.90), respetively. The ROC curve for the FIT
in the detection of AA in the PPI users and non-PPI users was 0.60 (CI 95% 0.51–0.68) and
0.79 (CI 95% 0.72–0.86), respectively. The ROC curves for the FIT in the detection of CRC in
the PPI—users and non-PPI users were 0.94 (CI 95% 0.92–0.97) and 0.93 (CI 95% 0.89–0.97),
respectively.
Table 2. Prevalence of high risk symptoms according NICE Guideline criteria by PPI use.









Patients over the age of 40 years with rectal bleeding and diarrhoea for six
week
23 (4.3) 26 (5.4) 0.433
Patients over the age of 60 years with rectal bleeding for six weeks without
anal symptoms
32 (6.1) 15 (3.1) 0.027
Patients over the age of 60 years with diarrhoea for six weeks 66 (12.6) 47 (9.8) 0.174
Definitive palpable right-sided abdominal mass 1 (0.01) 0 (0) 0.340
Rectal mass 4 (0.07) 1 (0.02) 0.215
Iron deficiency anemia 94 (18.6) 26 (5.4) < 0.001
https://doi.org/10.1371/journal.pone.0203359.t002
Table 3. Diagnostic accuracy of positive faecal immunochemical test (FIT 20 μg/g) for advanced neoplasia
according to PPI treatment.
PPI users Non PPI users P=
Sens 43.0 65.6 0.009
Spec 86.9 92.3 0.010
PPV 34.4 55.5 0.007
NPV 90.5 94.8 0.019
OV 80.9 88.8
PPI: proton pump inhibitor, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative
predictive value, OV: overall value.
https://doi.org/10.1371/journal.pone.0203359.t003
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Evaluation of false positives. In our study, the false positive (FP) rate produced by the
FIT for the detection of AN and CRC were 10.6% and 13.9%, respectively. In univariate analy-
sis, the proportion of FIT FP results for the detection of AN was higher in the PPI users than
in the non-PPI users (13.1% vs 7.7%; P = 0.013). The presence of rectal bleeding and diarrhea
over 40 years old patients (18.3% vs 8.6%; P = 0.020) and the presence of IDA (15.8% vs 8.9%;
P = 0.006) were also associated with FIT FP results for the detection of AN. Other high risk
signs or symptoms according NICE criteria as well as gender, dyslipidemia, smoking status,
high risk consumption of alcohol, diabetes, NSAID/antiplatelet agents users were not associ-
ated with FIT FP results for the detection of AN.
In the multivariate analysis for the diagnosis of AN, PPIs therapy, IDA and rectal bleeding
and diarrhea over 40 years old patients were associated with a FIT FP result after adjusting for
age, gender, smoking status, dyslipidemia, diabetes, NSAIDs and antiplatelet therapy and
other high risk symptoms according NICE criteria (see Table 5). Furthermore, in patients
without AN (n = 869), the faecal haemoglobin (f-Hb) concentration mean was higher in the
PPI-users (n = 453) than in the non-PPI users patients (n = 416) (median and interquartile
ranges were: 1.0 μg Hb/g feces [0–5.4] vs 0.2 μg Hb/g feces [0–4.0]; P = 0.005).
Regarding the detection of colorectal cancer, male gender and the presence of IDA were
both associated with FIT FP results (15.5% vs 11.4%; P = 0.037 and 19.1% vs 12.6%; P = 0.038,
respectively). The proportion of FITFP results for the detection of colorectal cancer was also
higher in PPI users than in non-PPI users, but the difference was not statistically significant
(14.9% vs 12.5%; P = 0.282).
Evaluation of false negatives. In our study, the false negative (FN) rate produced by FIT
for the detection of AN and CRC were 46.6% and 6.6%, respectively. The FIT FN rate for the
detection of AN was higher in the PPI users than in the non-PPI users (56.3% vs 35.5%;
P = 0.024). In the multivariate analysis, PPI treatment was not associated with a FIT FN result
after adjusting for age, gender, IDA and, NSAIDs and antiplatelet therapy. Nevertheless, in
patients with AN (n = 133), the f-Hb concentration was lower in the PPI-users (n = 70) than in
Table 4. Diagnostic accuracy of positive faecal immunochemical test (FIT 20 μg/g) for colorectal cancer accord-
ing to PPI treatment.
PPI users Non PPI users P =
Sens 93.3 93.3 0.759
Spec 85.1 87.4 0.289
PPV 15.5 19.4 0.515
NPV 99.7 99.7 0.760
OV 85.3 87.6
PPI: proton pump inhibitor, Sens: sensitivity, Spec: specificity, PPV: positive predictive value, NPV: negative
predictive value and OV: overall value.
https://doi.org/10.1371/journal.pone.0203359.t004
Table 5. Multivariate predictors of false positive result of faecal immunochemical test (FIT 20 μg/g) for diag-
nosing advanced neoplasia.
Variable OR (95% CI) P Value
Iron deficiency anaemia 1.84 (1.05–3.23) 0.032
Rectal bleeding and diarrhea over 40 years old 2.46 (1.15–5.32) 0.021
PPI treatment 1.63 (1.02–2.59) 0.037
PPI: proton pump inhibitors
https://doi.org/10.1371/journal.pone.0203359.t005
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the non-PPI users patients (n = 60) (median and interquartile ranges were: 15.4 μg Hb/g
feces [0.1–132.7] vs 64.2 μg Hb/g feces [3.5–192.1], P = 0.047). In addition, in patients with
advanced adenoma, excluding CRC (n = 103), f-Hb concentration was lower in the PPI-users
(n = 56) than in the non-PPI users patients (n = 45) (median and interquartile ranges were:
4.2 μg Hb/g feces [0.0–35.2] vs 26.1 μg Hb/g feces [2.1–139.7], P = 0.025).
Discussion
Identifying the factors that modify the accuracy of FIT could improve its usefulness as a bio-
marker of significant colorectal disease. Our study demonstrates that the accuracy of FIT in
the detection of AN clearly decreases in symptomatic patients undergoing PPI treatment.
Recently, a systematic review was performed by Westwood et al to evaluate the diagnostic
performance of FIT to detect AN and CRC in patients with lower abdominal symptoms. In
this study the sensitivity and the specificity summary estimate of FIT 20 μHb/g for AN were
64% and 86%, respectively, consistent with the sensitivity and the specificity values found in
our study, 53% and 89%, respectively. Regarding CRC, the sensitivity and the specificity sum-
mary estimate of FIT 20 μHb/g were 93% and 86%, respectively, closely similar to our results
of 93% sensitivity and 87% specificity [24]. Similarly, the accuracy of FIT 20 μHb/g for CRC
found in our study was also comparable to that found in asymptomatic average risk population
in CRC screening programs (89% sensitivity and 91% specificity) [25].
PPIs are the first line treatment for many gastrointestinal conditions and this therapy is
often overprescribed [26]. In line with this, more than half of the patients (52.4%) in our series
were on PPI treatment. Recently, a variety of effects of PPIs on the small and large bowel have
been described. Its use has been found to predispose patients to NSAID induced small bowel
injury, promote changes in the gut microbiome and inhibit pancreatic secretion [15–20]. To
date, there are no studies that evaluate the relationship between PPI treatment and the accu-
racy of FIT in the diagnosis of AN. We have found that the proportion of FP and FN FIT
results in the detection of AN were significantly higher in the PPI users than in the non-PPI
users (11.2 vs 6.7; P = .013 and 7.7 vs 4.3; P = 0.024, respectively). In patients with AN the
mean value of f-Hb is significantly lower in the PPI users than the non-PPI users (15.4 vs 64.2;
P = 0.047) that leads to FN results. Therefore, in patients with AN who are undergoing treat-
ment with PPI, the median value of f-Hb is lower than the value taken as the cut off, resulting
in an increased number of FN results.
Several factors have been associated with FP results in the FIT in screening programme for
CRC, including female gender and younger age [27]. A recently published study by Ibáñez-
Sanz et al, identified female gender, successive screening, haemorrhoids or anal fissure, and
PPI use to be risk factors for FP results in CRC screening programme [21]. Their results are
consistent with those of our study. We found that PPI use was an independent variable associ-
ated with FP of FIT in the detection of AN after adjusting for age, gender, smoking status, dys-
lipidemia, diabetes and NSAIDs and antiplatelet agents use. The mechanism by which PPI
therapy impairs the accuracy of FIT in the detection of AN is unknown but several possibilities
may be hypothesized. Firstly, PPI treatment could be a surrogate of small-bowel NSAID
induced injury. Several studies, including an RCT, reported a raised incidence of NSAID
induced injuries in PPI users [28]. Small intestinal dysbiosis caused by the marked suppression
of gastric acid secretion has been implicated in this effect. In addition, bacterial genes associ-
ated with epithelial invasion have been identified after PPI treatment in healthy subjects [29–
31]. This effect could play a role in the loss of accuracy of FIT. Secondly, PPI treatment could
impair the organ specificity of the FIT. The FIT has a high degree of selectivity for colorectal
bleeding due to the fact that human globin from lesions located proximal to the colon are
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readily degraded by proteases and do not positivize the test. Wang et al demonstrated that
PPI use inhibits pancreatic secretion in both rat and human pancreatic cells [20]. It might be
argued that the FIT, in patients undergoing PPI treatment, is able to detect undigested globin
from upper GI bleeding, resulting in a false positive.
Conversely, the increase of false negative FIT results in patients with PPI and AN was a
unexpected finding without consistent explanation and for which a fortuitous association can-
not be excluded. Therefore, this data should be taken with caution and should be confirmed in
subsequent studies.
The strengths of this study include its prospective design, which provides endoscopic
information about both FIT positive and FIT negative patients. Despite the availability of
studies dealing with the accuracy of the FIT, many are performed in screening programs
and endoscopic information is only available from FIT positive patients. Factors affecting
FN are difficult to study given that it requires performing colonoscopies in patients
with negative FIT. Another of the strengths of the study was that the use of drugs was rigor-
ously evaluated through the initial interview and confirmed in the electronic prescription
registry.
This study has several limitations. Firstly, it was performed in a tertiary care hospital, which
may lead to a selection bias [6]. Nevertheless, most of the patients were referred from primary
care and the rate of ANs found (13.3%) was similar to that found in other open-access endos-
copy units in our region. Secondly, the fact that the study population only included symptom-
atic patients already referred for colonoscopy may be another source of bias. However, ours is
an open-access endoscopy unit that belongs to the public health service and referral physicians
have a low threshold for the referral of patients for colonoscopy. Third limitation is the small
number of CRC. We found a significant difference in accuracy of FIT between PPI users and
no-PPI users for the detection of advanced adenoma and advanced neoplasia but not for
detecting CRC, presumably because of the small number of CRC cases. Finally, our results
might not be generalizable to CRC screening population. The characteristics of the neoplastic
lesions found in the asymptomatic average risk population may differ from those found in our
symptomatic population leading to differences in the accuracy of the FIT due to a spectrum
effect [32].
In summary, our study shows that PPI therapy impairs the performance of FIT for the
detection of AN in symptomatic patients. Given the widespread use of these drugs in the gen-
eral population, the negative impact on screening CRC programs may be substantial. The
effect of PPI therapy need to be investigated in screening population due to this therapy could
modify the accuracy of FIT in a CRC screening programme. Further studies are required to
confirm these findings and to determine whether cut-off values of FIT should be modified in
PPI users or whether PPI should be discontinued (and when) before FIT testing.
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10. Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, et al. Colonic cancer comparison of CT
colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced
adenoma in an average risk population. Gut. 2009; 58(2): 241–248. http://dx.doi.org/10.1136/gut.2008.
156448 PMID: 18852257
11. deWijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, et al. Immu-
nochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
Am J Gastroenterol. 2012; 107(10): 1570–1578. http://dx.doi.org/10.1038/ajg.2012.249 PMID:
22850431
12. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointest
Endosc Clin N Am. 2002; 12(1):1–9, v. PMID: 11916153
13. Godberg IM, Todd LM, Fraser CG, MacDonald LR, Younes HB. Use of a faecal immunochemical test
for haemoglobin can aid in the investigation of patients with lower abdominal symptoms. Clin Chem Lab
Med. 2016; 54(4): 595–602. http://dx.doi.org/10.1515/cclm-2015-0617 PMID: 26457785
14. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means get-
ting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical
test for hemoglobin (FIT). Gut Liver. 2014; 8(2):117–30. http://dx.doi.org/10.5009/gnl.2014.8.2.117
PMID: 24672652
15. Schoenfeld A, Grady D. Adverse effects associated with proton pump inhibitors. JAMA Intern Med.
2016; 176(2):172–174. http://dx.doi.org/10.1001/jamainternmed.2015.7927 PMID: 26751904
16. AbrahamNS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012; 28(6):
615–20. http://dx.doi.org/10.1097/MOG.0b013e328358d5b9 PMID: 23010681
17. Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointes-
tinal microbiome. Clin Lab Med. 2014; 34(4): 771–85. http://dx.doi.org/10.1016/j.cll.2014.08.008 PMID:
25439276
18. Washio E, Esaki M, Maehata Y, Miyazaki M, Kobayashi H, Ishikawa H, et al. Proton pump inhibitors
increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: A randomized,
placebo-controlled trial. Clin Gastroenterol Hepatol. 2016; 14(6): 809–815. http://dx.doi.org/10.1016/j.
cgh.2015.10.022 PMID: 26538205
19. Wang J, Barbuskaite D, Tozzi M, Giannuzzo A, Sørensen CE, Novak I. Proton pump inhibitors inhibit
pancreatic secretion: Role of gastric and non-gastric H+ /K+ -ATPases. PLoSONE 10(5): e0126432.
http://dx.doi.org/10.1371/journal.pone.0126432 PMID: 25993003
20. Foltz E, Azad S, Everett ML, Holzknecht ZE, Sanders NL, Thompson JW, et al. An assessment of
human gastric fluid composition as a function of PPI usage. Physiol Rep. 2015; 3(1). http://dx.doi.org/
10.14814/phy2.12269 PMID: 25626870
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